This is a working overview of PPARδ, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
== Detroit Lions == It has been said that Detroit Lions' announcer Van Patrick applied the nickname "Fearsome Foursome" to the Lions front four as early as 1960, when the Lion defensive line consisted of ends Bill Glass and Darris McCord, and tackles Alex Karras and Roger Brown. Other reports state that sportswriter Bruno Kerns of the Pontiac Press first used the Fearsome Four nickname for the Lions' defensive line in 1960. The Fearsome Foursome name for the Lions' defensive line continued after Sam Williams replaced Glass in 1962; Glass being traded to the Cleveland Browns for quarterback Milt Plum after the 1961 season. Other than 1963, McCord, Karras, Brown and Williams started together from 1962 through 1965; until Williams was taken by the Atlanta Falcons in the 1966 expansion draft. Karras missed the 1963 season as he was suspended in connection with alleged gambling. Their most well-known game was the 1962 "Thanksgiving Day Massacre" game against the Green Bay Packers, where they sacked Bart Starr 11 times (seven by Brown) and broke the Packers 12-game winning streak. The group's early defensive coordinator was future Pro Football Hall of Fame head coach Don Shula. Karras is in the Pro Football Hall of Fame. The 6 ft 5 in (1.96 m) 300 pound (136 kg) Brown, was one of the first NFL lineman to play at 300 pounds or more, with the speed and agility to make him highly effective at that weight. Brown was named to the Pro Bowl as a Lion from 1962 through 1966 and first-team All-Pro twice (1962-63).
=== Pseudobulbar affect === Pseudobulbar affect (PBA) is a condition involving episodic uncontrollable laughter or crying. PBA mostly occurs in people with neurological injuries affecting how the brain controls emotions. Scientists believe PBA results from prefrontal cortex damage. PBA often involves crying. Hence, PBA is mistakable for depression. But PBA is neurological; depression is psychological. Patients with PBA do not experience typical depression symptoms like sleep disturbances or appetite loss.
On July 4, ceremonies took place at Lincoln Financial Field in Philadelphia (Paraguay vs France) and NRG Stadium in Houston (Canada vs Morocco) to honor the United States Semiquincentennial. The Houston ceremony featured pyrotechnics, video-board graphics, and a performance of "The Star-Spangled Banner" by United States Navy Band Chief Musician Maia Rodriguez. The Philadelphia ceremony featured pyrotechnics, video-board signage, and a performance of "The Star-Spangled Banner" by Idina Menzel, as well as musical performances by the Roots, ceremonial elements featuring the Philadelphia Boys Choir & Chorale and Miss Pennsylvania, Stephanie Skinner, a card stunt, a flyby of VFA-11 and VFA-81 squadrons from Naval Air Station Oceana, and a halftime show from DJ Jazzy Jeff.
Kennedy, E P (2001), "Hitler's gift and the era of biosynthesis", J. Biol. Chem., vol. 276, no. 46 (published Nov 16, 2001), pp. 42619–31, doi:10.1074/jbc.R100051200, PMID 11559714 Young, V R; Ajami, A (1999), "The Rudolf Schoenheimer Centenary Lecture. Isotopes in nutrition research", The Proceedings of the Nutrition Society, vol. 58, no. 1 (published Feb 1999), pp. 15–32, doi:10.1079/pns19990004, PMID 10343336 Olson, R E (1997), "The dynamic state of body constituents (Schoenheimer, 1939)", J. Nutr., vol. 127, no. 5 Suppl (published May 1997), pp. 1041S–1043S, PMID 9164302 Guggenheim, K Y (1991), "Rudolf Schoenheimer and the concept of the dynamic state of body constituents.", J. Nutr., vol. 121, no. 11 (published Nov 1991), pp. 1701–4, doi:10.1093/jn/121.11.1701, PMID 1941176 Ratner, S; Rittenberg, D; Keston, A S; Schoenheimer, R (1987), "The Journal of Biological Chemistry, Volume 134, June 1940: Studies in protein metabolism. XIV. The chemical interaction of dietary glycine and body proteins in rats. By S. Ratner, D. Rittenberg, Albert S. Keston, and Rudolf Schoenheimer", Nutr. Rev., vol. 45, no. 10 (published Oct 1987), pp. 310–2, doi:10.1111/j.1753-4887.1987.tb06338.x, PMID 3320825 Shemin, D (1987), "On the impact on biochemical research of the discovery of stable isotopes: the outcome of the serendipic meeting of a refugee with the discoverer of heavy isotopes at Columbia University", Anal. Biochem., vol. 161, no. 2 (published Mar 1987), pp.
Sources: en.wikipedia.org
Specifically, 80% of the escitalopram users who experienced TdP were taking at least one other drug known to cause TdP. For comparison, the most popular antiarrhythmic drug in the study was sotalol with 52,750 users, and sotalol had a TdP incidence of 81.1 cases and 41.2 cases of TdP per 100,000 users in the ≥65 and 18-to-64-year-old demographics, respectively. Drugs that prolong the QT interval, such as escitalopram, should be used with caution in those with congenital long QT syndrome or known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. ECG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before starting treatment. In December 2011, the UK implemented new restrictions on the maximum daily doses at 20 mg for adults and 10 mg for those older than 65 years or with liver impairment. The US Food and Drug Administration and Health Canada did not similarly order restrictions on escitalopram dosage, only on its predecessor citalopram. Like other SSRIs, escitalopram has also been reported to cause hyponatremia (low sodium levels), with rates ranging from 0.5 to 32%, which can often be attributed to SIADH. This is typically not dose-dependent and at higher risk for occurrence within the first few weeks of starting treatment.
Chanut told Lemaire: "Our first two albums were a bit of tests. We were very Sludge, very Stoner, with influences not well digested yet". Drago said that 2012's Hope /// Dope /// Rope marked a slight sonic evolution. Drago further said that before This Is Not Supposed To Be Positive, their metal had been "until then placed on doom/stoner/sludge perfusion". This Is Not Supposed To Be Positive introduced cold wave synthesiser sounds, actually derived from guitar effects, along with gothic melodies, which would become a main sonic layer. In his review of This Is Not Supposed To Be Positive, Patrick Schmidt of Rock Hard stated that the quartet primarily belonged to the "doom/sludge scene". Banlieue Triste is characterised by profuse use of reverb and chorus effects. Hangman's Chair have been described as a "French doom rock band" or as sludge in its early days or "stoner", which led Thépegnier to acknowledge that being categorised within the doom scene did not bother the band members because their instruments are tuned "very low" and they play at slow tempos. "We sounded Sludge in our beginning", he said, adding, "I think we moved away from that pretty quickly". Thépegnier refuted any association with the "stoner" genre, further saying, "We are very far from Stoner, both in terms of imagery and the 'psychedelic rock' side". For A Loner, the group returned to work for the sixth time with Francis Caste, a French record producer and sound engineer, at his own Studio Sainte-Marthe in the 10th arrondissement of Paris.
Caspar Wistar, known for advocating compulsory vaccination; Benjamin Smith Barton, a botany and Native American culture expert; and Dr. Benjamin Rush, a Declaration signatory interested in the medicinal properties of cinchona bark. Humboldt's companion, Charles Willson Peale, a painter and lay scientist, introduced him to his unique museum, dubbed the "School of Wisdom." The museum held an eclectic array of specimens, including stuffed animals, bizarre artifacts, and a collection of paintings for sale. Peale also showcased a device called the physiognotrace, which allowed individuals to trace silhouettes, and Humboldt participated in creating a series of his own profiles.
Sources: en.wikipedia.org
The first Masons in Cuba were most likely Speculative and Operative, not Symbolic, and arrived by the early half of the 18th Century, as indicated by archaeological evidences of Masonic symbols that were found carved into the stones of the Convent of San Francisco as Mason's marks, which have been relatively dated to its current construction beginning in 1716, the year before Symbolic Freemasonry was established in England. These symbols were carved by operative stonemasons who had been brought into the country by the Catholic Church from disparate parts of the European continent to work on the construction project. At that time, Operative Masonic and Speculative Masonic guilds in Spain were not centralized, functioning instead as independent and unique Lodges, and it was not until 1728 that they formed the unified body of Freemasonry in Spain. The Convent of San Francisco did also receive renovations in 1731, but Havana's official City Historian, Eusebio Leal Spengler, stated during an inspection of the site that the marks were part of the construction of the convent and were not added anytime after the first half of the 18th Century. In 1738, ten years after Symbolic Freemasonry arrived in Spain, Pope Clement XII issued a Papal bull banning the practice of Freemasonry in the Catholic church. Following this, the Grand Inquisitor of Spain issued an edict banning the practice within the Spanish church by punishment of excommunication and a fine. In 1750, José Torrubia, while working for the Holy Office of the Inquisition in Madrid, went undercover as a Freemason in Spain.
where wt = Density of the wound area at time t ct = Density of the cell area at time t The above are basic metrics that can be measured with this assay. However efforts are still being made to improve the interpretation of this assay. Three different measurements: direct rate average, regression rate average and average distance regression rate have been evaluated. Direct rate average and average distance regression rate were more resistant to outliers, whereas regression rate average were more sensitive to outliers.
In fact, while ONJ was demonstrated in the RCTs of the two IV bisphosphonates dosed at higher dose and more frequently in patients with cancer, ONJ was not seen in meta-analysis of all of the osteoporosis RCTs that comprised the Fosamax clinical development program, or in an FDA analysis of all of the RCTs of 2–10 years in duration comprising almost 100,00 patient-years of RCT data from the clinical development programs for alendronate sodium (Fosamax), risedronate sodium (Actonel) ibandronate sodium (oral Boniva), ibandronic acid (IV Boniva), and zoledronic acid (Reclast). Bone: alendronate has been linked in long-term users to the development of low-impact femoral fractures. Further, studies suggest that users of alendronate have an increase in the numbers of osteoclasts and develop giant, more multinucleated osteoclasts; the significance of this development is unclear. Fosamax has been linked to a rare type of leg fracture that cuts straight across the upper thigh bone after little or no trauma (subtrochanteric fractures).
Body mass index (BMI) is a value used to get a general sense of a person's overall mass and is calculated using a person's height and weight. It is more often used than weight alone to determine if an individual is underweight, normal weight, overweight, or obese. The following two equations can used to calculate BMI depending on the units used for height (meters vs. inches) and weight (kilograms vs. pounds):
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.